Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan and Fludarabine Conditioning for AML and MDS
NCT00491634Phase 2Completed
- Start
- Jun 2007
- Primary completion
- Jun 2014
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Primary endpoint: Disease-Free Survival at 2 years. Started Jun 2007; status: completed.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00491634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491634.